W
W. Keith Hoots
Researcher at National Institutes of Health
Publications - 66
Citations - 6041
W. Keith Hoots is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Haemophilia & Von Willebrand disease. The author has an hindex of 28, co-authored 65 publications receiving 5649 citations. Previous affiliations of W. Keith Hoots include University of Texas at Austin & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
Marilyn J. Manco-Johnson,Marilyn J. Manco-Johnson,Thomas C. Abshire,Amy D. Shapiro,Brenda Riske,Michele R. Hacker,Ray F. Kilcoyne,J. David Ingram,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,Leonard A. Valentino,W. Keith Hoots,George R. Buchanan,Donna DiMichele,Michael Recht,Deborah L Brown,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +29 more
TL;DR: Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A.
Journal Article
Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation* On behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the ISTH
TL;DR: This poster presents a poster presented at the European Hemophilia and Vascular Biology Conference in Brussels, Belgium, which aims to present a probabilistic picture of the immune system’s response to blood clotting disorders.
Journal ArticleDOI
Prospective, Randomised Trial of Two Doses of rFVIIa (NovoSeven) in Haemophilia Patients with Inhibitors Undergoing Surgery
TL;DR: Although the 35 microg/kg dose is probably sub-optimal for post-operative management, at least in major procedures, rFVIIa 90 microg /kg is an effective first-line option in surgery for patients with inhibitors.
Journal ArticleDOI
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature.
TL;DR: A review of the published literature over the last 30 years found that PCCs offer a rapid and specific method for replacing vitamin K‐dependent clotting factors and restoring normal hemostasis in the context of over‐coagulation.
Journal ArticleDOI
Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
Chengwen Li,Nattee Narkbunnam,Nattee Narkbunnam,Richard Jude Samulski,Aravind Asokan,Genlin Hu,L. J. Jacobson,M. J. Manco-Johnson,Paul E. Monahan,Marilyn J. Manco-Johnson,Brenda Riske,Ray F. Kilcoyne,M L Manco-Johnson,Sharon Funk,Linda J. Jacobson,J. David Ingram,Thomas C. Abshire,Thomas C. Abshire,Amy D. Shapiro,Michele R. Hacker,Leonard A. Valentino,W. Keith Hoots,Deborah L Brown,George R. Buchanan,Donna DiMichele,Michael Recht,Cindy A. Leissinger,Shirley Bleak,Alan R. Cohen,Prasad Mathew,Alison Matsunaga,Desiree Medeiros,Diane J. Nugent,Gregory Thomas,Alexis A. Thompson,Kevin McRedmond,J. Michael Soucie,Harlan Austin,Bruce L. Evatt +38 more
TL;DR: The results may guide rational design of clinical trials using alternative AAV serotypes and suggest that younger patients who are given AAV gene therapy will benefit from the lower prevalence of NAbs.